PWRM, Power 3 Medical Products Inc., PWRM.OB has signed a definitive agreement recently to acquire all of the stock of Rozetta-Cell Life Sciences, Inc. Power3 plans to effectuate the acquisition of Rozetta-Cell by merging Rozetta-Cell with and into Power3, with Power3 remaining as the surviving company in the merger.
The acquisition of Rozetta-Cell is expected to be completed in October or November 2010.
Rozetta-Cell is a medical biotechnology company that focuses on the delivery and imaging of stem cells during therapy. The company has a robust intellectual property portfolio and has created numerous products for adult stem cell therapy that are ready for market globally. Rozetta-Cell also has several collaborations in process through which it is partnering with industry-leading adult stem cell research companies and adult stem cell vendors.
Power3 Medical Hits a Grand Slam at ICAD With Four Alzheimer’s Poster Presentations
Power3 Medical Products, Inc. announced a few weeks ago that it delivered four poster presentations at the 2010 International Conference on Alzheimer’s Disease (NASDAQ:ICAD) in Honolulu, Hawaii. These presentations discussed NuroProÂ®, Power3’s diagnostic test, and focused on Power3’s Alzheimer’s disease blood serum biomarkers, test and clinical validation trials.
“In preparation for commercialization, our objective at this meeting was to show how Power3’s protein biomarkers and blood tests provide superior solutions for diagnosis and drug response to improve the treatment of Alzheimer’s disease,” said Dr. Ira L. Goldknopf, Power3’s President and Chief Scientific Officer.
“It was gratifying to receive substantial attention to our posters from representatives of major pharma and clinical research institutions from around the world. They expressed surprise and enthusiasm for our findings, especially those relating to the methods by which Power3’s protein biomarkers indicate how patients respond to treatment with the three major anti-dementia drugs.”
About the Company
Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig’s disease). Power3 applies proprietary methodologies to discover and identify protein biomarkers associated with diseases.
Through these processes, Power3 has developed a portfolio of products including BC-SeraPro™, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroPro, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer’s, Parkinson’s and ALS diseases, for which it is currently engaged in Phase II clinical trials.
These tests are designed to analyze an individual’s proteins to detect the presence of disease, a patient’s disease progression, a patient’s response to a particular drug, and the mechanisms of disease present in the patient for optimal targeted therapy.
Penson Worldwide Inc (NasdaqGS:PNSN) announced on November 1, 2010 a net loss of $9.4 million, or ($0.33) per share, for the third quarter ended September 30, 2010, which included a pre-tax severance charge of $2.2 million, equal to ($0.05) per share net of tax. Third quarter net revenues totaled $69.8 million, reflecting $12.2 million from the former Ridge Clearing correspondents (whose contracts were acquired June 25, 2010) and a $13.0 million decline in Penson’s other businesses as compared to the second quarter ended June 30, 2010. This decline was primarily due to a 22% reduction in non-interest revenues, in line with industry average daily trading volumes, which were off more than 27% in equities and more than 21% in options compared to the second quarter.
Penson Worldwide, Inc., through its subsidiaries, provides various critical securities and futures processing infrastructure products and services to the financial services industry. Its products and services include securities and futures clearing and execution, clearing and custody services, trade settlement, technology services, risk management services, and customer account processing and customized data processing services, as well as financing and cash management technology and other related products.
Lattice Semiconductor Corporation (NasdaqGM:LSCC) announced the immediate availability of the PCI Express Root Complex (RC) Lite solution based on the LatticeECP3™ and LatticeECP2M™ FPGA families for use in simple bridging application to any legacy host bus. Using a low cost programmable FPGA platform, designers can implement the specific bridge function that matches the interface available on their particular host CPU. Designers will also have the flexibility to implement multiple bridges or different configurations of bridges in a single FPGA, reducing the number of components on the board.
Lattice Semiconductor Corporation designs, develops, and markets programmable logic products and related software. It offers field programmable gate array (FPGA) products, including LatticeECP family for deployment in wireless infrastructure and wireline access equipment, as well as in video and imaging applications; LatticeXP for the security, surveillance, and display markets; and LatticeSC family that combines an FPGA fabric with many features to meet the needs of communication system designs.
Corinthian Colleges Inc. (NasdaqGS:COCO) announced November 2, 2010 its financial results for the first quarter ended September 30, 2010. The results for the first quarter were within previous guidance ranges for new student growth and earnings per share. During the first quarter we continued to invest in areas which help improve student outcomes, reduce the risk profile of our student population, and ensure regulatory compliance,” said Peter Waller, Corinthian’s chief executive officer. “Our new student growth in the quarter was primarily driven by implementation of new programs at existing campuses, continued growth in the Online Learning division, the Heald acquisition, and the expansion of our high school recruiting program.
Corinthian Colleges, Inc., a post-secondary education company, provides various diploma programs, as well as associate’s, bachelor’s, and master’s degrees in the United States and Canada.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DoubleInStocks.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. The views expressed in any article, reports, writings are not necessarily the views of Crown Equity Holdings Inc. its officers, directors, staff, contractors or employees. They do not represent the views or opinions of this site. Views expressed in articles are those of the author alone. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. (Read more at: http://doubleinstocks.com/disclaimer) Release of Liability: Through use of this website viewing or using, you agree to hold DoubleInStocks.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services from Power 3 Medical Products Inc. (OTC:PWRM).